Radiotherapy of extramedullary plasmacytoma of the head and neck

The purpose of this study is to report the results of megavoltage irradiation in 23 previously unreported cases of extramedullary plasmacytoma of the head and neck. It has been found that 3500 cGy (rad) in three weeks provides good local control of disease with minimal morbidity and a significant proportion do not go on to multiple myeloma. Prognostic factors of significance with respect to subsequent development of multiple myeloma include site and presence or absence of bone destruction. The presence or absence of an M protein peak appears to be of no significance.     

MR characteristics of primary extramedullary plasmacytoma in the head and neck.

PURPOSETo define MR characteristics of primary extramedullary plasmacytoma in the head and neck using a variety of plain and contrast-enhanced MR protocols.METHODSSix patients with primary extramedullary plasmacytoma in the head and neck were examined clinically and with MR imaging at 1.5 T. The morphologic appearance and signal intensities of the lesions were analyzed and the results of the imaging findings were compared with histopathologic findings.RESULTSQualitative analysis showed that five lesions were oval and sharply demarcated without signs of infiltration; the other lesion filled the parapharyngeal space bilaterally. On t2-weighted sequences, the lesions had moderate signal intensity. On plain T1-weighted sequences, the tumors were isointense or slightly hyperintense with respect to surrounding muscles; after administration of contrast medium, four lesions notable enhancement, with distinct central inhomogeneity.CONCLUSIONAlthough morphologic features or evidence of contrast enhancement do not assure certain diagnosis of extramedullary plasmacytoma, these MR imaging characteristics should prompt the radiologist to include this rare lesion in the differential diagnosis.     

Dysphagia after definitive radiotherapy for head and neck cancer

Background

Dysphagia is a complication of head and neck cancer patients undergoing radiotherapy (RT). We analysed frequency and severity of swallowing dysfunction and correlated these findings with dose–volume histograms (DVHs) of the pharyngeal constrictor muscles.

Methods

A total of 50 patients treated by radical RT were enrolled. DVHs of constrictor muscles were correlated with acute and late dysphagia and with the items of three quality of life questionnaires.

Results

Mean dose to superior and middle constrictor muscles (SCM, MCM), partial volume of SCM and MCM receiving a dose ≥?50 Gy dose to the whole constrictor muscles ≥?60 Gy and tumour location were associated to late dysphagia at univariate analysis. Mean dose to the MCM was the only statistically significant predictor of late dysphagia at the multivariable analysis.

Conclusion

The study shows a significant relationship between long-term dysphagia and mean doses to SCM, MCM, whole constrictor muscles, and oropharyngeal tumour. This finding suggests a potential advantage in reducing the RT dose to swallowing structures to avoid severe dysphagia.     

Indications for and results of radiotherapy of plasmacytomas

In therapy of plasmocytoma the radiotherapy has a well established place in addition to chemotherapy. At the Clinic and Policlinic for Radiology of the Medical Academy Erfurt 42 patients with a plasmocytoma were treated in the years 1967 to 1987, 38 of them were included into the presented study. In radiotherapy roentgen depth-therapy was used with total surface dose of 30 to 40 Gy as well as telecobalt therapy with TD of 40 to 50 Gy. 8 patients had a solitary plasmocytoma, in three times with extramedullary manifestation in mucosa of cheek and nose and in gingiva and five times with bone localisation. In 30 patients with a multiple plasmocytoma we irradiated 37 painful bone lesions; for 29 of these irradiated findings the patients stated painlessness or distinct mitigation. In two bone manifestations a pathological fracture existed additionally, in which a complete painlessness and a clear callus formation could be attained. 4 patients with an incomplete cross-section syndrome in consequence of vertebral destruction with extradural tumor spreading responded with clear mitigation and regression of paresis. Furthermore an infiltration into soft parts was diagnosed at 9 bone foci, that were reduced in part (6 infiltrations) or regressed completely (3 findings) after radiotherapy. Additionally to osseous manifestations an extramedullary tumor (peribronchial lymph-nodes, hypophysis) existed in 2 patients, that regressed completely after termination of radiotherapy. The following indications can be mentioned for radiotherapy in plasmocytoma: 1. Curative postoperative radiotherapy after exstirpation of a solitary extramedullary plasmocytoma, 2. Curative sole radiotherapy of a solitary extramedullary of medullary plasmocytoma after its histological proving.(ABSTRACT TRUNCATED AT 250 WORDS)     

Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers

Radiotherapy and surgery are the principal curative modalities in treatment of head and neck cancer. Conventional two-dimensional and three-dimensional conformal radiotherapy result in significant side effects and altered quality of life. Intensity-modulated radiotherapy (IMRT) can spare the normal tissues, while delivering a curative dose to the tumour-bearing tissues. This article reviews the current role of IMRT in head and neck cancer from the point of view of normal tissue sparing, and also reviews the current published literature by individual head and neck cancer subsites. In addition, we briefly discuss the role of image guidance in head and neck IMRT, and future directions in this area.     

Radiologic manifestations of primary solitary extramedullary and multiple solitary plasmacytomas

OBJECTIVE: Primary solitary extramedullary and multiple solitary plasmacytomas are rare manifestations of plasma cell tumors. This study reviews their imaging spectrum in 12 patients. CONCLUSION: Imaging features of primary solitary extramedullary and multiple solitary plasmacytomas are nonspecific but are compatible with solid tumors that are isointense on T1-weighted images and iso- to hyperintense on T2-weighted images relative to muscle and white matter with variable enhancement. Large tumors may show necrosis and destruction, infiltration, or encasement of adjacent structures. Multiplicity of lesions and regional lymphadenopathy were evident on imaging in only five cases each. Imaging alone cannot differentiate these tumors from more common malignant entities such as carcinoma, meningioma in cases of intracranial extramedullary plasmacytomas, or metastasis from other primaries. The role of imaging should be focused on early detection of additional or recurrent lesions and the presence of regional lymphadenopathy, which will influence clinical management.     

Concomitant chemo/radiotherapy for advanced carcinoma of the head and neck

Giving chemotherapy and radiotherapy simultaneously (concomitant therapy) is one approach to improving results in advanced head and neck cancer. To assess the feasibility of one such regimen, 25 patients with advanced squamous carcinoma of the head and neck were treated with a continuous intravenous infusion of 5-fluorouracil, 1 g/m2 per 24 h for Days 1-5 (105 h) and mitomycin-C 14 mg/m2 intravenously on Day 3 during the first week of radiotherapy. Twenty had Stage IV disease; four Stage III; and one Stage II. Ages ranged from 21 to 73 years (median 60 years). The tumours involved were as follows: oral cavity (6); nasopharynx (8); oropharynx (5); secondary node from unknown primary (3); hypopharynx (2); paranasal sinus (1). Radiotherapy was delivered as 10 Gy per week (total dose 60-70 Gy). Chemotherapy was well tolerated and all received the intended dose. Mild nausea occurred in five patients and three experienced transient vomiting. A generalized "early" mucositis affected 16 out of 25 (64%), caused interruption of radiotherapy in three patients, and is thought to be chemotherapy related. Twenty-two patients received the dose of radiotherapy intended, and two stopped prematurely at 53 and 56 Gy. Three episodes of neutropaenic infection occurred. Two recovered uneventfully, but one toxic death occurred in a patient with alcoholic cirrhosis. A complete response was seen in 21 (84%). For 17 patients with non-nasopharyngeal carcinoma the 2-year survival is 40%, 24% disease free. The concomitant use of 5-fluorouracil, mitomycin and radiotherapy is well tolerated in this group of patients.     

Radiation induced sarcomas of the head and neck following radiotherapy for nasopharyngeal carcinoma

AIM: To report the radiological findings of radiation induced sarcomas (RIS) in the head and neck following radiotherapy for nasopharyngeal carcinoma. MATERIALS AND METHODS: The clinical notes and radiological studies (MR n = 3, CT n = 4) of four patients were reviewed retrospectively. RESULTS: RIS developed 5 to 10 years following radiotherapy. Two patients had tumours arising from the alveolar process of the maxilla, one from the nasal cavity, and one patient had a tumour at two sites, involving the external auditory canal and the uvula. Three of the four patients had large tumours at diagnosis with a 3.5-6 cm predominately homogeneous soft tissue mass, complete destruction of bone and extensive local invasion. One was small and localized to the nasal turbinate. Radiation osteitis was identified in two of the four (50%) patients. CONCLUSION: The site of RIS following radiotherapy for NPC is variable but is invariably within the high dose zone of the radiotherapy. These sarcomas tend to present late with a large soft tissue mass. Radiation osteitis is not a constant feature. As surgery provides the only chance of cure, imaging has an important role in the pre-operative mapping of the extent of tumour. et al.     

Possibilities in current radiotherapy of head and neck malignancies

Radio-oncology ranks highly in the treatment concept of tumours of the head and neck. Radiotherapy alone yields excellent rates of remission and cure with good cosmetic and functional results if applied in an early stage. Advanced tumours require the use of combined treatment modalities including surgery, radiotherapy and chemotherapy. The results of radiotherapy show a close relation to the applied dose in the target volume. This dose depends on the histology of the tumour, its localisation, its size, and the extent of involvement of lymph nodes. Radio-oncologically one can expect an increase in the rate of cure in higher tumour stages by the use of interstitial brachycurie therapy, intraoperative radiotherapy, hyperthermia and the employment of radiosensitisers of low toxicity. Close interdisciplinary cooperation is essential for achieving the best possible success of treatment.     

Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and-IV carcinomas of the head and neck

Purpose

To assess the survival rate, the probability of local control, the patterns of relapse and late sequelae including self-reported quality of life in patients treated with hyperfractionated radiotherapy (RT) and simultaneous CDDP chemotherapy for stage-III to stage-IV carcinomas of the head and neck.

Methods

From 1988 to 1994, 64 patients (median age 55.5 years) with carcinomas of different subsites, excluding the nasopharynx, were treated in a pilot study with 1.2 Gy bid (6 h interval; total dose 74.4 Gy) and simultaneous CDDP (20 mg/m² daily, 5 days in week 1 and 5) and followed at regular intervals. Overall survival and local control, as well as the rates of late toxicity, were estimated using the actuarial method. Median follow-up was 3.3 years for all and 5.2 years for surviving patients. To assess the quality of life, the EORTC QLQ-C 30 questionnaire and the H&N35 module questionnaire were sent to the patients surviving with no evidence of disease or second primary tumors; they were answered by 15/23 (67%).

Results

Overall survival was 37% at 5 years, whereas disease-specific survival was 59%. Twenty-three patients died from uncontrolled head and neck cancer. Second primary tumors were observed in 13 patients, most frequently in the lung. Local control without salvage surgery was 74% at 5 years for all subsites and stages, and loco-regional disease-free survival was 72%. Eleven patients developed distant metastases, which was the only site of failure in 6 cases. Salvage surgery was successful in 2 cases. The actuarial estimates of ≥ grade-3 late toxicity was 4% for the mandibular bone and 23% for dysphagia, and 50% of the patients experienced a permanent xerostomy. Self-reported global quality of life in surviving patients was good (mean 68 points on a scale 0 to 100); consequences of impaired salivary function had most impact on nutritional and social aspects.

Conclusions

Hyperfractionated RT with concomitant CDDP is well tolerated and highly efficient in controlling moderately advanced to advanced cancers of the head and neck. Second primary tumors are the main cause of death after 3 years and were observed outside of the irradiated area, most frequently in the lung. Even after RT of large volumes to a high dose, salvage surgery can be successfully performed in individual cases. Self-reported quality of life of surviving patients is good, despite xerostomy-associated nutritional difficulties.     

Is VMAT beneficial for patients undergoing radiotherapy to the head and neck?

Volumetric Intensity-Modulated Arc Therapy (VMAT) offers solutions to the time consuming, higher monitor unit (MU) delivery of Intensity-Modulated Radiotherapy (IMRT) for patients undergoing radiotherapy for head and neck cancer (HNC). Thus the aim was to determine whether VMAT would be beneficial for these patients.The majority of literature was planning comparative studies with only two studies on early clinical experience. Main themes arising from literature were conformity and homogeneity, organs at risk (OAR), MU and delivery time.VMAT provides plans with similar conformity, better homogeneity and results for improved sparing of OAR compared to IMRT. Thus it is clear that VMAT would be able to match the performance of IMRT plans, with the ability to treat patients in a short space of time and less MU. There is little clinical data on the side effects of VMAT, and more is needed to further evaluate the efficacy of VMAT. Overall these are encouraging results of VMAT for patients with HNC.     

Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings

The aim of this study was to evaluate the outcome and prognosticators for patients with resectable head and neck cancer (RHNC) undergoing definitive concurrent chemotherapy and radiotherapy (CCRT). In total, 110 RHNC patients receiving definitive CCRT to defer radical surgery were enrolled. Radiotherapy was given as either 2 Gy once daily with 70 Gy, or 1.2 Gy twice daily with 74.4 Gy. Chemotherapy involved the administration of 5-fluorouracil and cisplatin in two concomitant and two post-radiotherapy adjuvant cycles. 3 months after CCRT, MRI was performed to evaluate the response and determine further treatment plans. Survival outcome was calculated by the Kaplan-Meier method. Log-rank test and Cox regression analyses were used to estimate the significance of prognosticators. 4-year local-regional control, distant metastasis-free survival, disease-free survival and overall survival rates were 76.1%, 85.6%, 67.5% and 53.2%, respectively. Local recurrence (odds ratio = 4.09; p < 0.0001) and T3/T4 stage (odds ratio = 2.34; p = 0.01) were the independent factors associated with poor survival. T stage (odds ratio = 3.29; p = 0.03) and/or remission status on post-CCRT MRI (odds ratio = 7.22; p < 0.0001) were significantly associated with local control, distant metastasis-free survival and disease-free survival. 13 of 20 patients with imaging residuum had local recurrence, compared with 12 of 89 with complete remission (4-year local control rate of 27% vs 86%; p < 0.0001). Post-CCRT MRI may thus be used to predict the chance of a successful non-surgical approach.     

头颈部肿瘤放疗中转化医学相关机制的研究进展

头颈部肿瘤是目前世界上最常见的肿瘤之一,超过90%的头颈部肿瘤为鳞状细胞癌。放疗在头颈部肿瘤的治疗中显得尤为重要,目前国内治疗早期肿瘤可以单纯放疗为主,晚期肿瘤则选择综合性治疗。转化医学是近些年来新的研究重点,将科研过程及其成果与临床紧密结合,尤其体现在通过检测患者肿瘤组织中的基因突变靶点及基因单核苷酸多态性分型、mRNA基因定量表达,为临床提供靶向及个体化放疗的依据,能显著提高治疗的有效率。     

Intensity-modulated radiotherapy increases dose to the brachial plexus compared with conventional radiotherapy for head and neck cancer

Objective

The preferential use of intensity-modulated radiotherapy (IMRT) over conventional radiotherapy (CRT) in the treatment of head and neck cancer has raised concerns regarding dose to non-target tissue. The purpose of this study was to compare dose-volume characteristics with the brachial plexus between treatment plans generated by IMRT and CRT using several common treatment scenarios.

Method

The brachial plexus was delineated on radiation treatment planning CT scans from 10 patients undergoing IMRT for locally advanced head and neck cancer using a Radiation Therapy Oncology Group-endorsed atlas. No brachial plexus constraint was used. For each patient, a conventional three-g0ield shrinking-g0ield plan was generated and the dose-volume histogram (DVH) for the brachial plexus was compared with that of the IMRT plan.

Results

The mean irradiated volumes of the brachial plexus using the IMRT vs the CRT plan, respectively, were as follows: V50 (18±5 ml) vs (11±6 ml), p = 0.01; V60 (6±4 ml) vs (3±3 ml), p = 0.02; V66 (3±1 ml) vs (1±1 ml), p = 0.04, V70 (0±1 ml) vs (0±1 ml), p = 0.68. The maximum point dose to the brachial plexus was 68.9 Gy (range 62.3–78.7 Gy) and 66.1 Gy (range 60.2–75.6 Gy) for the IMRT and CRT plans, respectively (p = 0.01).

Conclusion

Dose to the brachial plexus is significantly increased among patients undergoing IMRT compared with CRT for head and neck cancer. Preliminary studies on brachial plexus-sparing IMRT are in progress.Although intensity-modulated radiotherapy (IMRT) is widely considered the current standard in the radiotherapeutic management of head and neck cancer, investigators are increasingly recognising that this technology is associated with significant beam path doses to non-target structures that previously received little dose using previous, less conformal techniques [1]. Indeed, since the clinical implementation of IMRT at our institution, we have observed a striking number of patients returning for follow-up with symptoms thought to be related to radiation-induced brachial plexopathy. The purpose of this study was to compare dose-volume characteristics to the brachial plexus between treatment plans generated by IMRT and conventional radiotherapy (CRT) using several common head and neck cancer treatment scenarios.     

MR imaging of osteoradionecrosis of the mandibula following radiotherapy for head and neck cancers

Magnetic resonance (MR) images of 13 patients with osteoradionecrosis of the mandibula were analyzed. Abnormalities were noted in all patients and could be classified into three groups. In nine patients, MR signals were homogeneously low in intensity on both T1 weighted images (T1WI) and T2 weighted images (T2WI), suggesting fibrosis of bone marrow. These nine patients had suffered radiologically and/or clinically overt osteoradionecrosis more than ten months previously, and inflammatory symptoms had settled down by the time of MR study. Two patients showed low signal intensity on T1WI and an area of inhomogeneous high intensity in a diffuse area of low signal intensity on T2WI, suggesting acute inflammation in the irradiated fibrous bone marrow. Both patients suffered pathologic fracture due to osteoradionecrosis and showed severe inflammatory symptoms at the time MR study. In one of the two patients, these pathologic changes were confirmed in surgically excised mandibulectomy specimens. The other two patients showed homogeneous low signal intensity on T1WI and high signal intensity on T2WI, a finding that may be due to slight inflammation. However, in one of the two patients, this signal feature possibly indicated loose fibrosis with marked cellularity.